[1] Lee, KiSS-1, a novel human malignant melanoma metastasis-suppressor gene (vol 88, pg 1731, 1996). Journal of the National Cancer Institute, 1997. 89(20): p. 1549-1549.

[2] West, A., et al., Chromosome localization and genomic structure of the KiSS-1 metastasis suppressor gene (KISS1). Genomics, 1998. 54(1): p. 145-8.

[3] Clarke, H., W.S. Dhillo, and C.N. Jayasena, Comprehensive Review on Kisspeptin and Its Role in Reproductive Disorders. Endocrinol Metab (Seoul), 2015. 30(2): p. 124-41.

[4] Topaloglu, A.K., et al., Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med, 2012. 366(7): p. 629-35.

[5] Ohtaki, T., et al., Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature, 2001. 411(6837): p. 613-617.

[6] Kotani, M., et al., The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. Journal of Biological Chemistry, 2001. 276(37): p. 34631-34636.

[7] Muir, A.I., et al., AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. Journal of Biological Chemistry, 2001. 276(31): p. 28969-28975.

[8] Mueller, J.K., et al., Transcriptional regulation of the human KiSS1 gene. Molecular and Cellular Endocrinology, 2011. 342(1-2): p. 8-19.

[9] Pinilla, L., et al., Kisspeptins and Reproduction: Physiological Roles and Regulatory Mechanisms. Physiological Reviews, 2012. 92(3): p. 1235-1316.

[10] Oakley, A.E., D.K. Clifton, and R.A. Steiner, Kisspeptin signaling in the brain. Endocr Rev, 2009. 30(6): p. 713-43.

[11] Navarro, V.M., et al., Regulation of gonadotropin-releasing hormone secretion by kisspeptin/dynorphin/neurokinin B neurons in the arcuate nucleus of the mouse. J Neurosci, 2009. 29(38): p. 11859-66.

[12] Topaloglu, A.K., et al., TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. Nature Genetics, 2009. 41(3): p. 354-358.

[13] Wakabayashi, Y., et al., Neurokinin B and Dynorphin A in Kisspeptin Neurons of the Arcuate Nucleus Participate in Generation of Periodic Oscillation of Neural Activity Driving Pulsatile Gonadotropin-Releasing Hormone Secretion in the Goat. Journal of Neuroscience, 2010. 30(8): p. 3124-3132.

[14] Seminara, S.B., Metastin and its g protein-coupled receptor, GPR54: Critical pathway modulating GnRH secretion. Frontiers in Neuroendocrinology, 2005. 26(3-4): p. 131-138.

[15] Smith, J.T., et al., Regulation of Kiss1 gene expression in the brain of the female mouse. Endocrinology, 2005. 146(9): p. 3686-3692.

[16] Uenoyama, Y., H. Tsukamura, and K.I. Maeda, Kisspeptin/Metastin: A Key Molecule Controlling Two Modes of Gonadotrophin-Releasing Hormone/Luteinising Hormone Release in Female Rats. Journal of Neuroendocrinology, 2009. 21(4): p. 299-304.

[17] Navarro, V.M., et al., Interactions between kisspeptin and neurokinin B in the control of GnRH secretion in the female rat. American Journal of Physiology-Endocrinology and Metabolism, 2011. 300(1): p. E202-E210.

[18] Lee, D.K., et al., Discovery of a receptor related to the galanin receptors. Febs Letters, 1999. 446(1): p. 103-107.

[19]  Seminara, S.B., et al., The GPR54 gene as a regulator of puberty. New England Journal of Medicine, 2003. 349(17): p. 1614-U8.

[20] Trevisan, C.M., et al., Kisspeptin/GPR54 System: What Do We Know About Its Role in Human Reproduction? Cellular Physiology and Biochemistry, 2018. 49(4): p. 1259-1276.

[21] Boyar, R., et al., Synchronization of augmented luteinizing hormone secretion with sleep during puberty. N Engl J Med, 1972. 287(12): p. 582-6.

[22] Beale, K.E., et al., The Physiological Role of Arcuate Kisspeptin Neurons in the Control of Reproductive Function in Female Rats. Endocrinology, 2014. 155(3): p. 1091-1098.

[23] Como, C. and P. Perego, KiSS1 in regulation of metastasis and response to antitumor drugs. Drug Resistance Updates, 2019. 42: p. 12-21.

[24] Dapas, M. and A.J.E.r. Dunaif, Deconstructing a Syndrome: Genomic Insights into PCOS Causal Mechanisms and Classification. 2022.

[25] March, W.A., et al., The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Human Reproduction, 2010. 25(2): p. 544-551.

[26] Rotterdam, E.A.-S.P.c.w.g., Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004. 19(1): p. 41-7.

[27] Fauser, B.C.J.M., et al., Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility, 2012. 97(1): p. 28-U84.

[28] Walters, K.A., M.J. Bertoldo, and D.J. Handelsman, Evidence from animal models on the pathogenesis of PCOS. Best Practice & Research Clinical Endocrinology & Metabolism, 2018. 32(3): p. 271-281.

[29] Dumesic, D.A., et al., Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev, 2015. 36(5): p. 487-525.

[30] Imani, B., et al., Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Journal of Clinical Endocrinology & Metabolism, 1998. 83(7): p. 2361-2365.

[31] Wang, R., et al., First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. Human Reproduction Update, 2019. 25(6): p. 717-732.

[32] Tagliaferri, V., et al., Melatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women With PCOS: A Pilot Study. Reproductive Sciences, 2018. 25(2): p. 269-275.

[33] Li, Y., et al., Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci, 2019. 228: p. 167-175.

[34] Naderpoor, N., et al., Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update, 2015. 21(5): p. 560-74.

[35] Patel, R. and G. Shah, Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats. Arch Med Res, 2018. 49(3): p. 154-163.

[36] Kumar, P. and S. Arora, Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates. J Hum Reprod Sci, 2014. 7(4): p. 255-61.

[37] Ruan, X., et al., Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Arch Gynecol Obstet, 2018. 297(6): p. 1557-1563.

[38] Wang, F.F., et al., Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis. Obesity Reviews, 2018. 19(10): p. 1424-1445.

[39] Salamun, V., et al., Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. European Journal of Endocrinology, 2018. 179(1): p. 1-11.

[40] Jamilian, M., et al., Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome. Nutrients, 2017. 9(12).

[41] Ergenoglu, M., et al., Effects of Resveratrol on Ovarian Morphology, Plasma Anti-Mullerian Hormone, IGF-1 Levels, and Oxidative Stress Parameters in a Rat Model of Polycystic Ovary Syndrome. Reproductive Sciences, 2015. 22(8): p. 942-947.

[42] Gozukara, I., et al., Histopathologic and metabolic effect of ursodeoxycholic acid treatment on PCOS rat model. Gynecol Endocrinol, 2016. 32(6): p. 492-7.

[43] Jahan, S., et al., Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats. J Ovarian Res, 2016. 9(1): p. 86.

[44] Wang, Z., et al., Quercetin Decreases Insulin Resistance in a Polycystic Ovary Syndrome Rat Model by Improving Inflammatory Microenvironment. Reprod Sci, 2017. 24(5): p. 682-690.

[45] Rajan, R.K., M.S.S. Kumar, and B. Balaji, Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism. Pharmaceutical Biology, 2017. 55(1): p. 242-251.

[46] Gozukara, I.O., et al., Effect of colchicine on polycystic ovary syndrome: an experimental study. Archives of Gynecology and Obstetrics, 2016. 293(3): p. 675-680.

[47] Marcondes, R.R., et al., Exercise differentially affects metabolic functions and white adipose tissue in female letrozole- and dihydrotestosterone-induced mouse models of polycystic ovary syndrome. Mol Cell Endocrinol, 2017. 448: p. 66-76.

[48] Goodman, N.F., et al., American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and Pcos Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 2. Endocrine Practice, 2015. 21(12): p. 1415-1426.

[49] Bordewijk, E.M., et al., Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. Cochrane Database of Systematic Reviews, 2020(2).

[50] Stephens, S.B.Z., et al., Absent Progesterone Signaling in Kisspeptin Neurons Disrupts the LH Surge and Impairs Fertility in Female Mice. Endocrinology, 2015. 156(9): p. 3091-3097.